What’s New in Intravenous Anaesthesia? New Hypnotics, New Models and New Applications

Vellinga, Remco; Valk, Beatrijs I.; Absalom, Anthony; Struys, Michel; Barends, Clemens

doi:10.3390/jcm11123493

Cited by 2 publications

(2 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, it is renowned for its remarkable potency, with specific studies suggesting it to be up to 10 times more potent than fentanyl. Sufentanil is currently under evaluation for various applications, and its distinctive properties position it as a promising option for intravenous anesthesia [46][47][48].…”

Section: Sufentanilmentioning

confidence: 99%

See 1 more Smart Citation

Exploring Ciprofol Alternatives: A Comprehensive Review of Intravenous Anesthesia Options

Durai Samy,

Taksande

2024

Cureus

View full text Add to dashboard Cite

Ciprofol is a recently developed, short-acting γ-aminobutyric acid receptor agonist sedative that is more potent than propofol. Still, there have been few clinical studies of this agent to date. This review explores alternative intravenous anesthesia options to ciprofol, considering their pharmacology, clinical efficacy, safety profile, and practical considerations. While ciprofol offers advantages such as rapid onset and predictable offset, concerns regarding its safety profile and individual variability in response have prompted the search for alternatives. Propofol, etomidate, ketamine, and dexmedetomidine are discussed as established options, each with unique characteristics and potential benefits. Emerging agents, including remimazolam, sufentanil, alfaxalone, and brexanolone, are examined for their potential role in anesthesia management. Recommendations for future research include large-scale comparative studies, optimization of dosing strategies, and personalized approaches guided by pharmacogenomic insights. Ultimately, the future of intravenous anesthesia lies in a multifaceted approach that integrates evidence-based practices, technological innovations, and individualized patient care to enhance safety, efficacy, and patient satisfaction across the perioperative continuum. Collaboration among stakeholders will be crucial in advancing the field and shaping the future landscape of intravenous anesthesia options.

show abstract

Section: Sufentanilmentioning

confidence: 99%

“…Notably, recovery from alfaxalone anesthesia sans supplementary drugs may be tumultuous, potentially leading to manifestations like paddling, vocalization, rigidity, and myoclonus in dogs and paddling and trembling in cats. As an emerging intravenous anesthetic agent, alfaxalone holds promise for clinical application [48][49][50][51].…”

Section: Alfaxalonementioning

confidence: 99%